Ensuring rights & welfare of human subjects in research
Research conducted by NEOMED using human participants is overseen by the Institutional Review Board (IRB). The primary purpose of the NEOMED IRB is to facilitate the review, approval, modification, and disapproval of human subject research protocols, while ensuring the rights and welfare of human subjects are protected while participating in research. The NEOMED IRB is registered to review research governed by the Office of Human Research Protections (OHRP). NEOMED has partnered with Advarra, a commercial outside IRB, to provide review and oversite of research governed by the Federal Drug Administration (FDA).
Committee Coordinator: Trish Wilson, CRA, ext. 6364
For protocols which are above minimal risk and do not quality of exempt or expedited review:
- January 25, 2021 at 4 p.m.
- March 08, 2021 at 4 p.m.
- May 17, 2021 at 4 p.m.
- July 12, 2021 at 4 p.m.
- September 13, 2021 at 4 p.m.
- November 08, 2020 at 4 p.m.
All materials must be submitted two weeks prior to the full board meeting date. Submit all materials electronically to the Regulatory Affairs Coordinator at email@example.com.